Literature DB >> 9655740

Effects of rSP-C surfactant on oxygenation and histology in a rat-lung-lavage model of acute lung injury.

D Häfner1, P G Germann, D Hauschke.   

Abstract

We have tested two surfactant preparations with the same phospholipid (PL) composition, containing recombinant surfactant protein-C (rSP-C surfactant) and without SP-C (plain PL surfactant). The effects of rSP-C surfactant were compared with the bovine-derived surfactant preparations Alveofact, bLES, and Infasurf in a lung lavage model, with surfactant given 1 h after the last lavage. The effects of surfactant treatment on histopathologic changes (e.g., hyaline-membrane formation) and improvement of oxygenation were compared with changes in untreated controls. The surfactants were given in doses of 25, 50, and 100 mg PL/kg body weight. At 120 min after treatment, only the protein-containing surfactants showed a statistically significant increasing dose dependence with respect to improving oxygenation. The values were 318 +/- 120 mm Hg, 443 +/- 58 mm Hg, and 480 +/- 43 mm Hg (mean +/- SD) for the three doses of rSP-C surfactant and 105 +/- 81 mm Hg, 100 +/- 69 mm Hg, and 131 +/- 108 mm Hg for the three doses of PL surfactant. The respective values for Alveofact were 104 +/- 81 mm Hg, 105 +/- 93 mm Hg, and 260 +/- 143 mm Hg; for bLES 373 +/- 138 mm Hg, 441 +/- 88 mm Hg, and 467 +/- 43 mm Hg; and for Infasurf 146 +/- 96 mm Hg, 284 +/- 178 mm Hg, and 436 +/- 70 mm Hg. The oxygen values of controls remained low, at 74 +/- 46 mm Hg. Only the protein-containing surfactants dose-dependently inhibited the formation of hyaline membranes. We conclude that rSP-C surfactant is at least as effective as bovine-derived surfactants. Furthermore, the data imply that the difference between plain PL surfactant preparations and bovine-derived surfactant preparations containing both SP-B and SP-C can be overcome by addition of SP-C.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655740     DOI: 10.1164/ajrccm.158.1.9712061

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  9 in total

1.  Optimisation of positive end-expiratory pressure by forced oscillation technique in a lavage model of acute lung injury.

Authors:  Raffaele L Dellacà; Emanuela Zannin; Peter Kostic; Marie Andersson Olerud; Pasquale P Pompilio; Goran Hedenstierna; Antonio Pedotti; Peter Frykholm
Journal:  Intensive Care Med       Date:  2011-04-01       Impact factor: 17.440

2.  Increased and prolonged pulmonary fibrosis in surfactant protein C-deficient mice following intratracheal bleomycin.

Authors:  William E Lawson; Vasiliy V Polosukhin; Georgios T Stathopoulos; Ornella Zoia; Wei Han; Kirk B Lane; Bo Li; Edwin F Donnelly; George E Holburn; Kenneth G Lewis; Robert D Collins; William M Hull; Stephan W Glasser; Jeffrey A Whitsett; Timothy S Blackwell
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

Review 3.  [Value of surfactant replacement therapy in the treatment of acute respiratory distress syndrome].

Authors:  S Lauer; L G Fischer; H D Stubbe; H Van Aken; M Westphal
Journal:  Anaesthesist       Date:  2006-04       Impact factor: 1.041

4.  Altered stability of pulmonary surfactant in SP-C-deficient mice.

Authors:  S W Glasser; M S Burhans; T R Korfhagen; C L Na; P D Sly; G F Ross; M Ikegami; J A Whitsett
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

5.  Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids.

Authors:  Philipp Markart; Clemens Ruppert; Malgorzata Wygrecka; Thorsten Colaris; Bhola Dahal; Dieter Walmrath; Heinz Harbach; Jochen Wilhelm; Werner Seeger; Reinhold Schmidt; Andreas Guenther
Journal:  Thorax       Date:  2007-02-07       Impact factor: 9.139

Review 6.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

7.  Suppressive effects of the expectorant drug ambroxol hydrochloride on quartz-induced lung inflammation in F344 rats.

Authors:  Shohei Kanie; Masanao Yokohira; Keiko Yamakawa; Yuko Nakano-Narusawa; Shota Yoshida; Nozomi Hashimoto; Katsumi Imaida
Journal:  J Toxicol Pathol       Date:  2016-12-22       Impact factor: 1.628

Review 8.  Positive end-expiratory pressure in acute respiratory distress syndrome: should the 'open lung strategy' be replaced by a 'protective lung strategy'?

Authors:  Jean-Jacques Rouby; Fabio Ferrari; Bélaïd Bouhemad; Qin Lu
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

Review 9.  A recipe for a good clinical pulmonary surfactant.

Authors:  Jesús Pérez-Gil
Journal:  Biomed J       Date:  2022-03-08       Impact factor: 7.892

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.